Thursday, July 17, 2025 | 12:13 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Ipca Lab hits 52-week high in a range-bound market; stk surges 9% in 3 days

According to Analysts at Phillip Capital, the company's revenues could grow 18 per cent year-on-year (YoY) to Rs 1,272.5 crore in June quarter of FY21

According to analysts at Prabhudas Lilladher, Ipca Labs is a global leader in anti-malaria drugs especially in supplying AL (Non-dispersible) medicines for The Global Fund procurement scheme and private sector co-payment mechanism
premium

According to analysts at Prabhudas Lilladher, Ipca Labs is a global leader in anti-malaria drugs especially in supplying AL (Non-dispersible) medicines for The Global Fund procurement scheme and private sector co-payment mechanism

SI Reporter New Delhi
Shares of Ipca Laboratories surged 8 per cent and hit a fresh 52-week high of Rs 1,883.65 on the BSE on Friday in an otherwise range-bound market. With today's gain, the stock has rallied 9 per cent in the past three trading sessions. 

In the June quarter of FY21, insurance companies raised stake in the company from 2.22 per cent stake, held at the end of Q4FY20, to 4.23 per cent. HDFC Life held 2.3 million shares, representing 1.82 per cent stake, while SBI Life held 1.4 million shares, representing 1.1 per cent stake, in the company at the end of